Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment

Inclusion Criteria

• •1. Histological diagnosis of marginal zone lymphoma of the ocular adnexae (OAMZL)
• •2. Single or bilateral lesion (stage IE) localised to the ocular adnexae (conjunctiva, lachrymal gland or sac, orbit soft tissue, eyelid)
• •3. Absence of B symptoms
• •4. Previously untreated patients
• •5. No systemic antibiotic therapy in the last three months before enrolment
• •6. Age \>18 years
• •7. ECOG PS 0-2
• •8. Negative HIV, HBV and HCV serology
• •9. Adequate bone marrow, renal, and hepatic function
• •10. No previous or concurrent malignancies with the exception of surgically cured carcinoma in situ of the cervix, carcinoma of the skin or other cancers without evidence of disease at least from 5 years
• •11. Absence of any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
• •12. Sexually active patients of childbearing potential must implement adequate contraceptive measures during study participation
• •13. No concurrent treatment with other experimental drugs
• •14. Patient-signed informed consent obtained before registration